+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Epigenetics Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 4520151
  • Report
  • May 2020
  • Region: Global
  • 115 Pages
  • Mordor Intelligence


  • Abcam PLC
  • Active Motiff
  • Diagenode Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc.
  • Merck & Co. Inc.
The epigenetics market is expected to register a CAGR of nearly 19.1% during the forecast period. Cancer rates may further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyle choices and actions for improving public health, by governments and health practitioners, can prevent as many as one-third of cancer cases, worldwide.

According to the World health Organization, in 2018, around 1.8 million new cases were diagnosed with cancer worldwide. According to the WHO, almost 70% of deaths from cancer occur in low - and middle-income countries, and only one in five low - and middle-income countries has the necessary data to drive cancer-related policies. This worldwide and extensive threat of cancer remains a major driver for the development of new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.

Resistance of cancers to the treatment is a major obstacle. However, epigenetic drugs, on their own or in combination with other drugs, can be a viable alternative. The epigenetic drug used in laboratory study stops the ability of cancer cells to hide from the immune system and makes the tumor vulnerable. Hence, the increasing prevalence of cancer is expected to augment the growth of the epigenetics market.

Key Market Trends

By Technology, DNA Methylation is Expected to Hold the Largest Share over the Forecast Period

DNA methylation dominated the epigenetics market, as it is the covalent addition of a methyl group in cytosine ring, which leads to the inhibition of transcription. Sensitive bisulfite modification, followed by PCR, is called methylation sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods, such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI - TOF MS, are also useful for DNA methylation. Advancements in technologies are increasingly enabling the assessment of locus-specific DNA methylation on a genome-wide scale.

North America Holds the Largest Share of the Epigenetics Market

North America dominates the epigenetics market, owing to the rapid developments in healthcare infrastructure, the presence of major players in the region, and huge investments made in the R&D. With increasing investments being made in the R&D of products by industries, an increase in the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines, are produced industrially. In the recent years, biopharmaceutical sales have reached 30% of all new pharmaceutical sales in the country. The United States accounts for the world’s largest expenditure on healthcare research. All these factors are expected to augment the growth of the market.

Competitive Landscape

Competition in the market is set to intensify, as several key players are focusing on the expansion of their epigenetics portfolio, through acquisitions of, and collaborations with other companies. The epigenetics market is expected to open up several opportunities for the new entrants and the currently established leading players.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Abcam PLC
  • Active Motiff
  • Diagenode Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc.
  • Merck & Co. Inc.

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Cancer
4.2.2 Increasing Funding for R&D in Healthcare
4.2.3 Rising Epigenetic Applications in Non-oncology Diseases
4.3 Market Restraints
4.3.1 Rising Costs of Instruments
4.3.2 Dearth of Skilled Researchers
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Instruments
5.1.2 Reagents & Kits
5.1.3 Others
5.2 By Application
5.2.1 Oncology
5.2.2 Autoimmune Diseases
5.2.3 Metabolic Diseases
5.2.4 CNS/Pain Diseases
5.2.5 Cardiovascular Diseases
5.2.6 Others
5.3 By Technology
5.3.1 Methylation
5.3.2 Acetylation
5.3.3 Phosphorylation
5.3.4 Other Technologies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abcam PLC
6.1.2 Active Motiff
6.1.3 Diagenode Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Illumina Inc.
6.1.6 Merck & Co. Inc.
6.1.7 Qiagen NV
6.1.8 Thermo Fisher Scientific
6.1.9 Zymo Research Corporation
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abcam PLC
  • Active Motiff
  • Diagenode Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc.
  • Merck & Co. Inc.
  • Qiagen NV
  • Thermo Fisher Scientific
  • Zymo Research Corporation
Note: Product cover images may vary from those shown